BEI
DGX icon

Benjamin Edwards Inc’s Quest Diagnostics DGX Stock Holding History

Benjamin Edwards Inc’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
7,447
-757
-9% -$149K 0.01% 643
2026
Q1 		$1.61M Buy
8,204
+776
+10% +$151K 0.02% 611
2025
Q4 		$1.29M Buy
7,428
+537
+8% +$97.8K 0.01% 626
2025
Q3 		$1.31M Buy
6,891
+140
+2% +$24.8K 0.01% 607
2025
Q2 		$1.21M Buy
6,751
+156
+2% +$27.1K 0.02% 566
2025
Q1 		$1.12M Buy
6,595
+1,922
+41% +$316K 0.02% 543
2024
Q4 		$705K Buy
4,673
+304
+7% +$47.3K 0.01% 726
2024
Q3 		$678K Buy
+4,369
New +$652K 0.01% 700
2024
Q1 		– Sell
-88
Closed -$12K – 720
2023
Q4 		$12K Buy
88
+13
+17% +$1.71K ﹤0.01% 574
2023
Q3 		$9K Buy
75
+28
+60% +$3.73K ﹤0.01% 580
2023
Q2 		$7K Buy
47
+5
+12% +$689 ﹤0.01% 593
2023
Q1 		$6K Sell
42
-31
-42% -$4.43K ﹤0.01% 616
2022
Q4 		$11K Buy
73
+15
+26% +$2.16K ﹤0.01% 568
2022
Q3 		$7K Buy
58
+50
+625% +$6.58K ﹤0.01% 587
2022
Q2 		$1K Buy
+8
New +$1.09K ﹤0.01% 685

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Benjamin Edwards Inc's DGX Position: Q2 2026 in Review

Benjamin Edwards Inc reduced its Quest Diagnostics (DGX) stake by 9.2% in Q2 2026, selling an estimated $149K and leaving 7,447 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #643.

Benjamin Edwards Inc first reported a position in DGX in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.61M in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Benjamin Edwards Inc held 7,447 shares of Quest Diagnostics worth $1.58M as of Q2 2026.
  • Benjamin Edwards Inc sold 757 Quest Diagnostics shares in Q2 2026, an estimated $149K.
  • Quest Diagnostics made up 0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #643 holding.
  • Benjamin Edwards Inc first reported a position in Quest Diagnostics in Q2 2022 and has held it in 15 quarters since.
  • Benjamin Edwards Inc's Quest Diagnostics position peaked at $1.61M in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.